资讯

The New England Journal of Medicine8月

Use of a New Compound, UML-491 (1-Methyl-D-Lysergic Acid Butanolamide ...

Results in Group 2 — Mixed Types (Solid-Black Columns Indicate Patients Receiving UML-491, and Crosshatched Columns Those Receiving a Placebo).